Akebia Therapeutics, Inc. (AKBA)

Over the past six months, Akebia Therapeutics' stock has increased by 34.07%, but decreased by 8.58% in the past month, closing at $3.03 on October 24, 2025. Key events include break-even earnings reported for Q2 2025, with revenue jumping 43%, the U.S. launch of Vafseo in January 2025, Jefferies initiating coverage with a "Buy" recommendation, the withdrawal of a Phase 3 pediatric anemia study for Vadadustat, and participation in healthcare conferences.

Specific information regarding demand seasonality for Akebia Therapeutics, Inc.'s products and services was not explicitly found. The demand for pharmaceutical products, particularly those addressing chronic conditions like kidney disease, may be less subject to seasonal fluctuations compared to consumer goods, but this cannot be definitively stated without direct evidence.

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney diseases. The company's major products include Auryxia, an FDA-approved oral medication for controlling serum phosphorus levels and treating iron deficiency anemia in adult patients with chronic kidney disease, and Vadadustat (marketed as Vafseo), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia due to CKD in both dialysis-dependent and non-dialysis-dependent adult patients.

Akebia Therapeutics is headquartered in Cambridge, Massachusetts. The company has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries. Mitsubishi Tanabe Pharma Corporation holds rights for vadadustat in Japan and other Asian countries.

Akebia Therapeutics aims to be a trusted leader in the renal community, delivering unique products to people with kidney disease, with a mission to improve the lives of those impacted by kidney disease through innovative therapies. The withdrawal of a Phase 3 clinical study for Vadadustat in pediatric patients with anemia of chronic kidney disease could affect its reputation, while positive news such as strong Q2 revenue performance for Auryxia and the ongoing launch and expansion efforts for Vafseo contribute positively.

Major institutional owners of Akebia Therapeutics include Vanguard Total Stock Market Index Fund Investor Shares, Satter Management Co., iShares Russell 2000 ETF, Geode Capital Management, and Renaissance Technologies. As of April 1, 2025, 242 funds or institutions reported positions in Akebia Therapeutics, an increase of 22 owners in the last quarter, with total shares owned by institutions increasing by 12.33% to 80.494 million shares.